President and professor of Sun Yat-sen University Cancer Center, Director of State Key Laboratory of Oncology in South China, Member of the Academic Committee of the Chinese Academy of Medical Sciences, Chairman of the Chinese Society of Clinical Oncology (CSCO), Vice-chairman of China Anti-cancer Association (CACA) and Editor in Chief of Cancer Communications.

Professor Xu has made profound contributions in the research and treatment of GI cancer, advancing both theory and practice in the field. His pioneering work has elevated China's GI cancer early diagnosis and precision treatment to an internationally advanced level. His ground breaking contributions have redefined the immunotherapy strategy for GI cancer, driving global progress in this specialized domain. His clinical research on Toripalimab, a domestically developed innovative PD-1 antibody, garnered FDA approval in the United States on October 28, 2023. This marks a historic milestone, as it's the first time Chinese original biological monoclonal antibodies have obtained US market approval.

He has published more than 200 peer-reviewed papers in top international journals such as JAMA, Cancer Cell,Nature Medicine, Nature Materials and Lancet Oncology. His standing as a "Highly Cited Researcher" by Clarivate Analytics underscores his influence and recognition within the scientific community. He was awarded 2 times of Prizes of the State Scientificand Technological Progress Award, and the National Innovation Competition Award.

For information on Professor Xu's laboratory, click here and select: Metastasis Molecular Mechanism/Biomarkers for Individual Therapy.

M.D. School of Medicine, Jiangxi Medical College, China, 1983-1988 

Master Degree in Oncology, Sun Yat-Sen University of Medical Sciences, China, 1991-1994

Ph.D in Oncology, Sun Yat-Sen University of Medical, China, 1997-2000

Selected publications

(2) Manish A Shah, Kohei Shitara, Jaffer A Ajani, Yung-Jue Bang, Peter Enzinger, David Ilson, Florian Lordick, Eric Van Cutsem, Javier Gallego Plazas, Jing Huang, Lin Shen, Sang Cheul Oh, Patrapim Sunpaweravong, Hwoei Fen Soo Hoo, Haci Mehmet Turk, Mok Oh, Jung Wook Park, Diarmuid Moran, Pranob Bhattacharya, Ahsan Arozullah, Rui-Hua Xu#. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023 Aug;29(8):2133-2141.

(3) Xu RH*#, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, Yi S, Shi W, Quan Q, Li K, Zheng L, Zhang H, Caughey BA, Zhao Q, Hou J, Zhang R, Xu Y, Cai H, Li G, Hou R, Zhong Z, Lin D, Fu X, Zhu J, Duan Y, Yu M, Ying B, Zhang W, Wang J, Zhang E, Zhang C, Li O, Guo R, Carter H, Zhu JK, Hao X and Zhang K. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater 2017; 16: 1155-1161. 

(4) Xu RH*#, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS and Kim TW. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 2018; 19: 660-671. 

(5) Li J, Qin S, Xu R*, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J and Kim TW. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology 2015; 16: 619-629. 

(6) Luo H, Xu G, Li C, He L, Luo L, Wang Z, Jing B, Deng Y, Jin Y, Li Y, Li B, Tan W, He C, Seeruttun SR, Wu Q, Huang J, Huang DW, Chen B, Lin SB, Chen QM, Yuan CM, Chen HX, Pu HY, Zhou F, He Y, Xu RH#. Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. Lancet Oncol. 2019 Oct 4. 

(7) Satoh T, Xu RH*, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A and Bang YJ. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. Journal of Clinical Oncology 2014; 32: 2039-2049. 

(8) Manish A. Shah, Rui-hua Xu*, Yung-Jue Bang, Paulo M. Hoff, Tianshu Liu, Luis A. Herr´aez-Baranda, Fan Xia,Amit Garg, Mona Shing, and Josep Tabernero. HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. Journal of Clinical Oncology 2017; 35: 2558-2567. 

(9) Yan-Xing Chen, Zi-Xian Wang, Ying Jin, Qi Zhao, Ze-Xian Liu, Zhi-Xiang Zuo, Huai-Qiang Ju, Chengxu Cui, Jun Yao, Yanqiao Zhang, Mengxia Li, Jifeng Feng, Lin Tian, Xiao-Jun Xia, Hui Feng, Sheng Yao, Feng-Hua Wang, Yu-Hong Li, Feng Wang, Rui-Hua Xu#. An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma. Cancer Cell. 2023 May 8;41(5):919-932.e5. doi: 10.1016/j.ccell.2023.03.016. Epub 2023 Apr 13.

Updated December 2023  by International Office, Sun Yat-sen University Cancer Center

Dr. Feng Wang is currently a professor, assistant president and director in the Department of Medical Oncology at Sun Yat-Sen University Cancer Center, Guangzhou, China. She has extensive experience and expertise in the field of Gastrointestinal Medical Oncology and translation research in gastrointestinal cancers. Dr Wang sees more than thousands of patients with gastrointestinal cancers annually and has initiated or participated in many investigators initiated and NMPA approved clinical trials. She presides over a number of research programs including the international (regional) cooperation and exchange program, and general program from the national natural science foundation of China, the Doctoral Program of Higher Education of China, and has participated in several international cooperation, national and provincial level projects. Dr. Wang has published over 105 peer-reviewed articles, including some first author or corresponding author papers in renowned journals such as Nature Medicine, Cancer Cell, Journal of Clinical Oncology, JAMA Oncology, Annals of Oncology, The Lancet Gastroenterology and Hepatology, Gut, etc and has been invited to present her research results at ASCO, AACR, CSCO, ESMO, JSCO, Nature Conference, Chinese Congress of Oncology and other international conferences. She is a member of the Guidelines Expert group that developed the European Society for Medical Oncology (ESMO) Pan-Asian Gastric Cancer Guidelines; Developed the CSCO Colorectal Cancer Guidelines as Secretary-General of the Guidelines Expert Group. She was awarded many prizes including the Second Prize of National Science and Technology Progress Award, First Prize of Chinese Medical Science and Technology Award, the First Prize of Guangdong Province Science and Technology Progress Award, "Important Medical Progress 2022" Award of Chinese Academy of Medical Sciences, Guangdong Youth May Fourth Medal etc. She holds many academic posts, including the Vice Chairman of Youth Council of China Anti-Cancer Association, vice director of Youth Committee of Professional Committee of Tumor Targeted Therapy, Chinese anti-cancer association and a Chairing Committee member of Chinese Society of Clinical Oncology etc. 

Sep 2008-Jun 2012
UT M.D. Anderson Cancer Center, PhD 

Jul 2008-Sep 2005
Sun Yat-sen University Cancer Center, MS

Sep 2000-Jul 2005
Jiangxi Medical College, Bachelor of Medicine

Selected publications

1. Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial. Yuan SQ, Nie RC, Jin Y, Liang CC, Li YF, Jian R, Sun XW, Chen YB, Guan WL, Wang ZX, Qiu HB, Wang W, Chen S, Zhang DS, Ling YH, Xi SY, Cai MY, Huang CY, Yang QX, Liu ZM, Guan YX, Chen YM, Li JB, Tang XW, Peng JS, Zhou ZW, Xu RH*, Wang F*. Nat Med. 2024.

2. Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study. Chen G, Jin Y, Guan WL, Zhang RX, Xiao WW, Cai PQ, Liu M, Lin JZ, Wang FL, Li C, Quan TT, Xi SY, Zhang HZ, Pan ZZ, Wang F*, Xu RH*. Lancet Gastroenterol Hepatol. 2023.

3. An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma. Chen YX, Wang ZX, Jin Y, Zhao Q, Liu ZX, Zuo ZX, Ju HQ, Cui C, Yao J, Zhang Y, Li M, Feng J, Tian L, Xia XJ, Feng H, Yao S, Wang FH, Li YH, Wang F*, Xu RH*. Cancer Cell. 2023.

4. Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II-III gastric cancer. Yuan SQ, Nie RC, Huang YS, Chen YB, Wang SY, Sun XW, Li YF, Liu ZK, Chen YX, Yao YC, Xu Y, Qiu HB, Liang Y, Wang W, Liu ZX, Zhao Q, Xu RH*, Zhou ZW*, Wang F*. Cancer Commun (Lond). 2023. 

5. Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis. Wu HX, Pan YQ, He Y, Wang ZX, Guan WL, Chen YX, Yao YC, Shao NY, Xu RH*, Wang F*. J Clin Oncol. 2023.

6. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H, Cang S, Jiang Y, Wang J, Ye M, Chen Z, Jiang D, Lin Q, Ren W, Wang J, Wu L, Xu Y, Miao Z, Sun M, Xie C, Liu Y, Wang Q, Zhao L, Li Q, Huang C, Jiang K, Yang K, Li D, Liu Y, Zhu Z, Chen R, Jia L, Li W, Liao W, Liu HX, Ma D, Ma J, Qin Y, Shi Z, Wei Q, Xiao K, Zhang Y, Zhang Y, Chen X, Dai G, He J, Li J, Li G, Liu Y, Liu Z, Yuan X, Zhang J, Fu Z, He Y, Ju F, Liu Z, Tang P, Wang T, Wang W, Zhang J, Luo X, Tang X, May R, Feng H, Yao S, Keegan P, Xu RH*, Wang F*. Cancer Cell. 2022.

7. Impact of mismatch repair or microsatellite status on the prognosis and efficacy to chemotherapy in metastatic colorectal cancer patients: A bi-institutional, propensity score-matched study. Yao YC, Jin Y, Lei XF, Wang ZX, Zhang DS, Wang FH, Li YH, Xu RH*, Wang F*. J Cancer. 2022.

8. A randomized, open-label, multicenter, phase 3 study of high-dose vitamin C plus FOLFOX +/- bevacizumab versus FOLFOX +/- bevacizumab in unresectable untreated metastatic colorectal cancer. Wang F, He MM, Xiao J, Zhang YQ, Yuan XL, Fang WJ, Zhang Y, Wang W, Hu XH, Ma ZG, Yao YC, Zhuang ZX, Zhou FX, Ying JE, Yuan Y, Zou QF, Guo ZQ, Wu XY, Jin Y, Mai ZJ, Wang ZQ, Qiu H, Guo Y, Shi SM, Chen SZ, Luo HY, Zhang DS, Wang FH, Li YH, Xu RH*. Clin Cancer Res. 2022.

9. Comprehensive profiling of 1015 patients' exomes reveals genomic-clinical associations in colorectal cancer. Zhao Q, Wang F*, Chen YX, Chen S, Yao YC, Zeng ZL, Jiang TJ, Wang YN, Wu CY, Jing Y, Huang YS, Zhang J, Wang ZX, He MM, Pu HY, Mai ZJ, Wu QN, Long R, Zhang X, Huang T, Xu M, Qiu MZ, Luo HY, Li YH, Zhang DS, Jia WH, Chen G, Ding PR, Li LR, Lu ZH, Pan ZZ, Xu RH*. Nat Commun. 2022.

10. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Wang F*, Huang YS, Wu HX, Wang ZX, Jin Y, Yao YC, Chen YX, Zhao Q, Chen S, He MM, Luo HY, Qiu MZ, Wang DS, Wang FH, Xu M, Li YH, Xu RH*. Gut. 2022.

11. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Chen G, Peng J, Xiao Q, Wu HX, Wu X, Wang F, Li L, Ding P, Zhao Q, Li Y, Wang D, Shao Y, Bao H, Pan Z, Ding KF, Cai S, Wang F*, Xu RH*. J Hematol Oncol. 2021.

12. POLE/POLD1 mutation in non-exonuclease domain matters for predicting efficacy of immune-checkpoint-inhibitor therapy. Chen YX, Wang ZX, Yuan SQ, Jiang TJ, Huang YS, Xu RH*, Wang F*, Zhao Q*. Clin Transl Med. 2021.

13. Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis. Wang F, He MM, Yao YC, Zhao X, Wang ZQ, Jin Y, Luo HY, Li JB, Wang FH, Qiu MZ, Lv ZD, Wang DS, Li YH, Zhang DS, Xu RH*. Cell Rep Med. 2021.

14. Baseline lesion number as an efficacy predictive and independent prognostic factor and its joint utility with TMB for PD-1 inhibitor treatment in advanced gastric cancer. Wei XL, Xu JY, Wang DS, Chen DL, Ren C, Li JN, Wang F*, Wang FH*, Xu RH*. Ther Adv Med Oncol. 2021.

15. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Jin Y, Chen DL, Wang F, Yang CP, Chen XX, You JQ, Huang JS, Shao Y, Zhu DQ, Ouyang YM, Luo HY, Wang ZQ, Wang FH, Li YH, Xu RH*, Zhang DS*. Mol Cancer. 2020.

16. Germline mutational profile of Chinese patients under 70 years old with colorectal cancer. Jiang TJ, Wang F, Wang YN, Hu JJ, Ding PR, Lin JZ, Pan ZZ, Chen G, Shao JY, Xu RH, Zhao Q, Wang F*. Cancer Commun (Lond). 2020.

17. Expert opinions on immunotherapy for patients with colorectal cancer. Wang F, Wang ZX, Chen G, Luo HY, Zhang DS, Qiu MZ, Wang DS, Pan ZZ, Shen L, Li J, Zhang SZ, Xu RH*. Cancer Commun (Lond). 2020.

18. AMPKα1 confers survival advantage of colorectal cancer cells under metabolic stress by promoting redox balance through the regulation of glutathione reductase phosphorylation. Wang YN, Lu YX, Liu J, Jin Y, Bi HC, Zhao Q, Liu ZX, Li YQ, Hu JJ, Sheng H, Jiang YM, Zhang C, Tian F, Chen Y, Pan ZZ, Chen G, Zeng ZL, Liu KY, Ogasawara M, Yun JP, Ju HQ, Feng JX, Xie D, Gao S, Jia WH, Kopetz S, Xu RH, Wang F*. Oncogene. 2020.

19. Inhibition of fatty acid catabolism augments the efficacy of oxaliplatin-based chemotherapy in gastrointestinal cancers. Wang Y, Lu JH, Wang F, Wang YN, He MM, Wu QN, Lu YX, Yu HE, Chen ZH, Zhao Q, Liu J, Chen YX, Wang DS, Sheng H, Liu ZX, Zeng ZL, Xu RH*, Ju HQ*. Cancer Lett. 2020.

20. Trastuzumab plus docetaxel and capecitabine as a first-line treatment for HER2-positive advanced gastric or gastroesophageal junction cancer: a phase II, multicenter, open-label, single-arm study. Wang F, Liu TS, Yuan XL, Luo HY, Gu KS, Yuan Y, Deng YH, Xu JM, Bai YX, Wang Y, Liao WJ, Zhang HL, Bi F, Wang BM, Zhuang ZX, Jiang TJ, Xu RH*. Am J Cancer Res. 2020.

21. Anti-PD-1 antibody SHR-1210 plus apatinib for metastatic colorectal cancer: a prospective, single-arm, open-label, phase II trial. Ren C, Mai ZJ, Jin Y, He MM, Wang ZQ, Luo HY, Zhang DS, Wu CY, Wang F*, Xu RH*. Am J Cancer Res. 2020.

22. Systematic analysis of the transcriptome in small-cell carcinoma of the oesophagus reveals its immune microenvironment. Zhao Q, Chen YX, Wu QN, Zhang C, Liu M, Wang YN, Feng YF, Hu JJ, Fu JH, Yang H, Qi JJ, Wang ZX, Lu YX, Sheng H, Liu ZX, Zuo ZX, Zheng J, Yun JP, Bei JX, Jia WH, Lin DX, Xu RH*, Wang F*. Clin Transl Immunology. 2020.

23. Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer. Liu F, Ren C, Jin Y, Xi S, He C, Wang F, Wang Z, Xu RH, Wang F*. Virchows Arch. 2020.

24. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, Xu RH*. JAMA Oncology. 2019.

25. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432. Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, Feng JF, Ba Y, Liu YP, Li W, Shu YQ, Jiang Y, Li Q, Wang JW, Wu H, Feng H, Yao S, Xu RH*. Annals of Oncology. 2019.

26. The genomic landscape of small cell carcinoma of the esophagus. Wang F, Liu DB, Zhao Q, Chen G, Liu XM, Wang YN, Su H, Qin YR, He YF, Zou QF, Liu YH, Lin YE, Liu ZX, Bei JX, Xu RH*. Cell Research. 2018.

Dr Li Zhang is Professor of Medical Oncology, Director of Phase I Unit of Sun Yat-Sen University Cancer Centre (SYSUCC), Deputy Director of Lung Cancer Research Centre of SYSU. He is also the member of ASCO, CSCO, ESMO, IASLC, MASCC and Member of communication committee of IASLC. Professor Zhang has published more than 200 clinical papers in top-tier journals like: Lancet, Lancet Oncology, Lancet Respiratory Medicine, Journal of Clinical Oncology, JAMA Oncology, Nature Communications, Annals of Oncology, JTO, JNCI. He also presented abstracts to many major congresses like ASCO, WCLC, ESMO, MASCC meetings.  He is an editorial board member of Clinical Lung Cancer, Chinese Journal of Clinical Oncology, and Cancer Communications. At present, he is a senior consultant to the Centre of Drug Evaluation, Chinese Food and Drug Administration (CFDA) and had formerly drafted the CFDA Guidance for Industry: Clinical Trial for the Approval of Cancer Drugs and Biologics (second version, 2006).

Dr Zhang received his master of clinical oncology degree from SYSU and was board certified as a physician in medical oncology. He has completed training as a visiting fellow at the MD Anderson Cancer Centre, Houston; Fox Chase Cancer Centre, Philadelphia, USA and Institut Gustave Roussy, Paris, France.

Selected publications

1. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.  Li Zhang, Y Huang, S Hong, Y Yang, G Yu, J Jia, P Peng, X Wu, Q Lin, X Xi, J Peng, M Xu, D Chen, X Lu, R Wang, X Cao, X Chen, Z Lin, J Xiong, Q Lin, C Xie, Z Li, J Pan, J Li, S Wu, Y Lian, Q Yang, C Zhao The Lancet 2016

2. Efficacy and tolerability data from a randomised, placebo-controlled, parallel-group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804). Li Zhang, S Ma, X Song, B Han, Y Cheng, C Huang, S Yang, X Liu, Y Liu, S Lu, J Wang, S Zhang, C Zhou, X Zhang, N Hayashi, M Wang.  Lancet Oncology 2012

3. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. W Fang, Y Yang, Y Ma, S Hong, L Lin, X He, J Xiong, P Li, H Zhao, Y Huang, Y Zhang, L Chen, N Zhou, Y Zhao, X Hou, Q Yang, Li Zhang  Lancet Oncology 2018

4. Challenges in anticancer drug R&D in China.  S Zhao, C Lv, J Gong, W Fang, X Hu, Y Ba, X Chen, Z Yang, L Shen, Li Zhang Lancet Oncology 2019

5. ALESIA: a randomised phase 3 study of alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer. C Zhou, S Kim, T Reungwetwattana, J Zhou, Y Zhang, J He, J Yang, Y Cheng, S Lee, L Bu, T Xu, L Yang, C Wang, T Liu, P N. Morcos, Y Lu, Li Zhang The Lancet Respiratory Medicine 2019

6. Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.     Y Yang, J Zhou, J Zhou, J Feng, W Zhuang, J Chen, J Zhao, W Zhong, Y Zhao, Y Zhang, Y Song, Y Hu, Z Yu, Y Gong, Y Chen, F Ye, S Zhang, L Cao, Y Fan, G Wu, Y Guo, C Zhou, K Ma, J Fang, W Feng, Y Liu, Z Zheng, G Li, N Wu, W Song, X Liu, S Zhao, L Ding, L Mao, G Selvaggi, X Yuan, Y Fu, T Wang, S Xiao, Li Zhang  The Lancet Respiratory Medicine 2020

7. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results.  Zhang L, Zhao C, Peng PJ, Lu LX, Huang PY, Han F, Wu SX.  Journal of Clinical Oncology 2005

8. Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non–Small Cell Lung Cancer. S Hong, F Gao, S Fu, Y Wang, W Fang, Y Huang, Li Zhang. JAMA Oncology 2018

9. The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma. Hong S, Liu D, Luo S, Fang W, Zhan J, Fu S, Zhang Y, Wu X, Zhou H, Chen X, Chen G, Zhang Z, Zheng Q, Li X, Chen J, Liu X, Lei M, Ye C, Wang J, Yang H, Xu X, Zhu S, Yang Y, Zhao Y, Zhou N, Zhao H, Huang Y, Zhang L, Wu K, Zhang Li. Nature Communications 2019

10. Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis.  Y Zhang, Y Yang, Z Zhang, W Fang, S Kang, Y Luo, J Sheng, J Zhan, S Hong, Y Huang, N Zhou, H Zhao, Li Zhang  Journal of The National Cancer Institute 2017

11. Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer. W Fang, Y Ma, J Yin, S Hong, H Zhou, A Wang, F Wang, H Bao, X Wu, Y Yang, Y Huang, H Zhao, Y Shao, Li Zhang Clinical Cancer Research 2019

Last updated: April 2020 by International Office, Sun Yat-sen University Cancer Center

The Preliminary Results of Advanced and Recurrent Malignant Lymphoma Treated by BEAC Regimen Supported with Autologous Hematopoietic Stem Cells Transplantation Chinese Huang Hui-qiang et al. Journal of Cancer Research(CJC) 2002 14(1):50-53

Preliminary outcome of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin’s lymphoma :single institution experience Bufei Wang ,Huiqiang Huang The Chinese-German Journal of Clinical Oncology 2006 Dec Vol5 Num 6（402）

Phase II clinical trial of Lopaplatin in the treatment of solid malignancies Jiang wen- qi Lin Tong-yi Huang Hui-qiang et al : International Journal of Modern Cancer Therapy 1999，33:312-5

Novantrone:A phase II trial in the treatment of advanced nasopharyngeal carcinoma in the People’s Republic of China Z.Z. Guan, H.Q. Huang , R. Rastogi Proceedings of American Society of Clinical Oncology(ASCO) 1993 : 12 (5) abstract 922

Updated by International Office, Sun Yat-sen University Cancer Center

2008----present Associate professor. Medical Breast Cancer Department, Cancer Center, Sun Yat-Sen University. August 2004----2007 Attending Doctor and lecturer, Medical Oncology Department, Cancer Center, Sun Yat-Sen University. Secretary of Expert Panel in Good Clinical Practice Center, Cancer Center, Sun Yat-Sen University.Secretary of medical department, Cancer Center, Sun Yat-Sen University.Secretary of Expert Panel in Medical Record Administration, Cancer Center, Sun Yat-Sen University.

Journal Reviewer
2010 Chinese Journal of Cancer

2009 Chinese Journal of CancerJournal Editor

2009 Global oncology express

Honors and Awards
2007 The Best Service Award of Cancer Center, Sun Yat-Sen University

2006 Excellent Paper Awards, the Fourth Chinese Conference on Oncology.

1993 The Best Service Award of First hospital of Xu zhou Mineral Bureau

1992 The Third rank Scholarship of Yangzhou Medical College.

Associations and Memberships
Member of Chinese Society of Clinical Oncology (CSCO).

Member of Guangdong Provincial Anticancer Association (GDACA)

Updated by International Office, Sun Yat-sen University Cancer Center

Professor Qingqing Cai has been engaged in clinical oncology work for more than 20 years, specializing in the area of clinical, translational, and basic research on lymphoma, nasopharyngeal carcinoma, head and neck squamous cell carcinoma. She served as the leader of the lymphoma Group of Guangdong Medical Association, and has won the "2020 People's Good Doctor" (Lymphoma) Outstanding Contribution Award”, the first batch of “Outstanding Young Medical Talents in Guangdong Province”, and other titles. In the past 5 years, she has published 17 articles as the corresponding author (or co-corresponding author) in prestigious journals including Blood, Leukemia, Clin Cancer Res, Signal Transduct Target Ther, etc., and presided over several national natural science foundations and provincial foundations. 

Specializes in clinical, transformation and basic research of lymphoma; and in clinical research on nasopharyngeal carcinoma, head and neck squamous cell carcinoma.

1. A composite single-nucleotide polymorphism prediction signature for extranodal natural killer/T-cell lymphoma patients undergoing non-anthracyline-based treatment: a retrospective, international, cohort study.Xiao-Peng Tian# ; Shu-Yun Ma# ; Ken H. Young# ; Choon Kiat Ong# ; Yan-Hui Liu# ; Zhi-Hua Li; Qiong-Li Zhai; Hui-Qiang Huang; Tong-Yu Lin; Zhi-Ming Li; Zhong-Jun Xia; Li-Ye Zhong; Hui-Lan Rao; Mei Li; Jun Cai; Yu-Chen Zhang; Fen Zhang; Ning Su; Peng-Fei Li; Feng Zhu; Zijun Y Xu-Monette; Esther Kam Yin Wong; Jeslin Chian Hung Ha; Lay Poh Khoo; Le Ai; Run-Fen Cheng; Jing Quan Lim; Sanjay de Mel; Siok-Bian Ng; Soon Thye Lim; Cai QQ*.Blood  2021.

2. Sequential P-GEMOX and radiotherapy for early-stage extranodal natural killer/T-cell lymphoma: A multicenter study.Yuchen Zhang#; Shuyun Ma#;  Jun Cai#;Yu Yang#; Hongmei Jing#;Yuerong Shuang; Zhigang Peng; Bingzong Li; Panpan Liu1;  Zhongjun Xia; Yi Xia1; Yan Gao; Daoguang Chen; Jianyang Lin; Qihui Li; Shenghua Xu; Qingyuan Xu; Han; Zhang; Huiqiang Huang *;  Qingqing Cai*.Am J Hematol 2021.

3. Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma.Jun Cai# ; Panpan Liu# ; Huiqiang Huang# ; Yajun Li; Shuyun Ma; Hui Zhou; Xiaopeng Tian; Yuchen Zhang; Yan Gao; Yi Xia; Xuanye Zhang; Hang Yang; Lirong Li; Cai QQ*.Signal Transduction and Targeted Therapy 2020.

4. A CpG methylation classifier to predict relapse in adults with T-cell lymphoblastic lymphoma.Tian XP# ; Su N# ; Wang L# ; Huang WJ# ; Liu YH; Zhang X; Huang HQ; Lin TY; Ma SY; Rao HL; Li M; Liu F; Zhang F; Zhong LY; Liang L; Lan XL; Li J; Liao B; Li ZH; Tang QL; Liang Q; Shao CK; Zhai QL; Cheng RF; Sun Q; Ru K; Gu X; Lin XN; Yi K; Shuang YR; Chen XD; Dong W; Sun C; Sang W; Liu H; Zhu ZG; Rao J; Guo QN; Zhou Y; Meng XL; Zhu Y; Hu CL; Jiang YR; Zhang Y; Gao HY; He WJ; Xia ZJ; Pan XY; Hai L; Li GW; Song LY; Kang TB; Xie D* ; Cai QQ*.CLINICAL CANCER RESEARCH 2020.

5. A gene-expression-based signature predicts survival in adults with T-cell lymphoblastic lymphoma: A multicenter study  Running Title: A Gene Classifier to Predict Adult T-LBL Prognosis.Tian XP# ; Xie D# ; Huang WJ# ; Ma SY# ; Wang L; Liu YH; Zhang X; Huang HQ; Lin TY; Rao HL; Li M; Liu F; Zhang F; Zhong LY; Liang L; Lan XL; Li J; Liao B; Li ZH; Tang QL; Liang Q; Shao CK; Zhai QL; Cheng RF; Sun Q; Ru K; Gu X; Lin XN; Yi K; Shuang YR; Chen XD; Dong W; Sang W; Sun C; Liu H; Zhu ZG; Rao J; Guo QN; Zhou Y; Meng XL; Zhu Y; Hu CL; Jiang YR; Zhang Y; Gao HY; He WJ; Xia ZJ; Pan XY; Lan H; Li GW; Liu L; Bao HZ; Song LY; Kang TB; Cai QQ*.Leukemia 2020.

6. BRD2 induces drug resistance through activation of the RasGRP1/Ras/ERK signaling pathway in adult T-cell lymphoblastic lymphoma.Xiao-Peng Tian* Jun Cai* Shu-Yun Ma* Yu Fang* Hui-Qiang Huang  Tong-Yu Lin  Hui-Lan Rao Mei Li  Zhong-Jun Xia Tie-Bang Kang Dan Xie Qing-Qing Cai# .Cancer Communications 2020.

7. Prognostic and predictive value of a microRNA signature in adults with T-cell lymphoblastic lymphoma.Tian XP# ; Huang WJ# ; Huang HQ# ; Liu YH; Wang L; Zhang X; Lin TY; Rao HL; Li M; Liu F; Zhang F; Zhong LY; Liang L; Lan XL; Li J; Liao B; Li ZH; Tang QL; Liang Q; Shao CK; Zhai QL; Cheng RF; Sun Q; Ru K; Gu X; Lin XN; Yi K; Shuang YR; Chen XD; Dong W; Sang W; Sun C; Liu H; Zhu ZG; Rao J; Guo QN; Zhou Y; Meng XL; Zhu Y; Hu CL; Jiang YR; Zhang Y; Gao HY; He WJ; Xia ZJ; Wu CL; Zhang MY; Wang HY; Xie D* ; Cai QQ* .Leukemia 2019.

8. Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma.Peng RJ# ; Han BW# ; Cai QQ# ; Zuo XY; Xia T; Chen JR; Feng LN; Lim JQ; Chen SW; Zeng MS; Guo YM; Li B; Xia XJ; Xia Y; Laurensia Y; Chia BKH; Huang HQ; Young KH; Lim ST; Ong CK* ; Zeng YX* ; Bei JX* ;.Leukemia 2019.

9. IL-2R alpha up-regulation is mediated by latent membrane protein 1 and promotes lymphomagenesis and chemotherapy resistance in natural killer/T-cell lymphoma. Wang L#* ; Bi XW# ; Zhu YJ; He YZ; Lai QY; Xia ZJ; Cai QQ*. Cancer Communications 2018.

10. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study. Hu, Li-Yang; Xu, Xiao-Lu; Rao, Hui-Lan; Chen, Jie; Lai, Ren-Chun; Huang, Hui-Qiang; Jiang, Wen-Qi; Lin, Tong-Yu; Xia, Zhong-Jun; Cai QQ*, Chinese Journal of Cancer, 2017.

Updated November 2021 by International Office, Sun Yat-sen University Cancer Center

Updated by International Office, Sun Yat-sen University Cancer Center

2010.08 -2010.12    Clinical observer, Breast Cancer Medicine service

Memorial Sloan-Kettering Cancer Center (MSKCC), New York, USA

2007.01-2012.12   Associate professor,

Department of medical oncology,

Cancer center of Sun Yat-sen University, China

2004.07- 2006.12   Lecturer & Attending Physician,

Department of medical oncology,

Cancer center of Sun Yat-sen University, China

1998.07 -2001.08    Lecturer & attending physician,

Affiliated hospital of Xuzhou Medical College, China

1992.07 -1995.08    Resident physician,

Affiliated hospital of Xuzhou Medical College, China

1. Familiar with medical oncology and phase I, II, III Clinical trials

2. Cell culture and purification of protein. 

3. In vitro and in vivo study of anti-cancer drugs

4. Molecular biological techniques

2001-2004 Ph.D. in Medical Oncology, Sun Yat-sen University, China

1995-1998 M.S. in Medical Oncology, Henan Medical University, China 

1987-1992 M.D. in Clinical Medicine, Xuzhou Medical College, China

1.       Fu L, Shi K, Wang J, ChenW, Shi D, Tian Y, Guo W, Yu W, Xiao X, Kang T, Wang S, Huang W, Deng W. TFAP2B overexpressioncontributes to tumor growth and a poor prognosis of human lung adenocarcinomathrough modulation of ERK and VEGF/PEDF signaling. Mol Cancer,2014,13:89  (corresponding author)

2.       Chen W, Qin L, Wang S, Li M, Shi D, Tian Y, Wang J, FuL, Li Z, Guo W, Yu W, Yuan Y, Kang T, Huang W, Deng W. CPSF4 activates telomerasereverse transcriptase and predicts poor prognosis in human lungadenocarcinomas. Mol Oncol. 2014May;8(3):704-716  (correspondingauthor)

3.       ZENG Yin-duo, XU Fei, QIN Tao,YANG Yan-hua,LIAO Yu-ting,Qin Ge,Wang Shu-sen. Toremifene inPostmenopausal Operable Patients with Luminal Subtype of Breast Cancer asCompared with Tamoxifen:A Retrospective Study in China. Chin J Bases ClinGeneral Surg,  2014,21( 5):555-561(correspondingauthor)

4.       Ma hongmin,Hu lingyu, Wang shusen.Diagnosis and Treatment for Occult Breast Cancer. Chin J BasesClin General Surg, 2014, 21( 5):544-548(corresponding author)　

5.       Qin T, Yuan ZY, PengRJ,Zeng YD,Shi YX, Teng XY,Liu DG, Bai B, WangSS .Efficacy andtolerability of toremifene and tamoxifen therapy in premenopausal patients withoperable breast cancer: a retrospective analysis. Curr Oncol,2013, 20(4):1-9  (correspondingauthor)

6.        Qin T, Yuan ZY, Peng RJ ,Shi YX, Teng XY,LiuDG, Bai B, Wang SS .HER2-positive breast cancer patients receivingtrastuzumab treatment obtain prognosis comparable with that ofHER2-negativebreast cancer patients. Onco Targets and Therapy.2013,6:341-47   (corresponding author)

7.       QIN Tao, YUAN Zhong-yu, PENGRou-jun, BAI Bing, SHI Yan-xia, TENG Xiao-yu, LIU Dong-geng, WANG Shu-sen. Efficacy and Safety of Toremifene in Young Patients with LuminalSubtype Early Breast Cancer： A Retrospective Study. JOURNAL OF SUN YAT-SEN UNIVERSITY（MEDICAL SCIENCES）,2013,34(3):402-406(corresponding author)

8.       Fu ly, Chen WB, Guo W, WangJS, Tian Y, Shi DB, Zhang XH,Qiu HJ, Xiao XS, Kang TB, Huang WL, Wang SS,Deng WG.Berberine Targets AP-2/hTERT, NF-κB/COX-2, HIF-1α/VEGF andCytochrome-c/Caspase Signaling to Suppress Human Cancer Cell Growth. PIOS ONE,2013,8(7):1-13  (correspondingauthor)

9.       Gu WG, Huang Y, YuanZY, Peng RJ, Luo HT, He ZR, Wang SS. ZD1839 and cisplatin aloneor in combination for treatment of a nasopharyngeal carcinoma cell line andXenografts. Asian Pac J Cancer Prev. 2013;14(3):1787-90 (correspondingauthor)

10.   Wangbing Chen, Wei Guo, Mei Li, Dingbo Shi, Yun Tian, Zhenlin Li,Jingshu Wang, Lingyi Fu, Xiangsheng Xiao, Quentin Qiang Liu, Shusen Wang, Wenlin Huang, Wuguo Deng. Upregulation of cleavageand polyadenylation specific factor 4 in lung adenocarcinoma and its criticalrole for cancer cell survival and proliferation. PLoS One. 2013;8(12):e82728 (corresponding author)

11.    Wang S, Shi Y,Yuan Z, Wang X, Liu D, Peng R, Teng X, Qin T, Peng J, Lin G, Jiang X. ClassicalCMF regimen as adjuvant chemotherapy for triple-negative breast cancer may bemore effective compared with anthracycline or taxane-based regimens. Med Oncol.2012,29:547-553 (first author)

12.    He J, Peng R, Yuan Z, Wang S, Peng J, Lin G, Jiang X, Qin T. Prognostic value of androgenreceptor expression in operable triple negative breast cancer: A retrospectiveanalysis based on a tissue microarray. Med Oncol 2012,29:406-410

13.     Liu D, He J,Yuan Z, Wang S, Peng R, Shi Y, TengX, Qin T. EGFR expression correlates with decreased disease-free survival intriple negative breast cancer: A retrospective analysis based on a tissuemicroarray. Med Oncol. 2012,29:401-405

14.   Shi YX, Tan YT,Yuan ZY, Wang SS, Peng RJ, An X, CaoY, Jin Y, Cai XY, Sun YL, Teng XY, Liu DG. Comparison of overall survivalbetween the early use and delayed use of Trastuzumab therapy groups: aretrospective analysis of 128 patients with HER-2-positive advanced breast cancer.Med Oncol 2012,29:39-47

15.   Shi YX, Xia Q,Peng RJ, Yuan ZY, Wang SS, An X, CaoY, Tan YT, Jin Y, Cai XY, Sun YL, Teng XY, Liu DG, Jiang WQ. Comparison ofclinicopathological characteristics and prognoses between bilateral andunilateral breast cancer. J Cancer Res Clin Oncol. 2012 ,138:705-714

16.    Wang x, Wang SS,Peng RJ, Qin T, Shi YX, Teng xy, Chen wq, Liu DG,  Yuan ZY. Interaction of coping styles andpsychological stress on anxious and depressive symptoms in Chinese breastcancer patients. Asian Pacific J Cancer Prev 2012; 13:1645-1649. （IF：1.24）

17.   PengR, Wang S, Shi Y, Liu D, Teng X, QinT, Zeng Y, Yuan Z. Patients 35 years old oryounger with operable breast cancer are more at risk for relapse and survival:A retrospective matched case-control study. Breast. 2011; 20: 568-573.（IF：2.089）

18.    Liu DG, WangSS, Peng RJ, Qin T, Shi YX, Teng XY, Wang X, Chen WQ, Yuan ZY. Interaction of Social Support andPsychological Stress on Anxiety and Depressive Symptoms in Breast CancerPatients. Asian Pacific J Cancer Prev 2011; 12:2523-2529. （IF：1.24）

19.   Bing Bai, Shusen Wang et al. Clinical Featuresand Survival Analysis of Different  Subtypesof   Patients with Breast Cancer BrainMetastases. Chinese Journal of Cancer, 2010,29(4): 453-461. (corresponding author)

20.   Qin jianyong Wang shusen,YIN CHUANZHONG The legaland ethic issues in operating medical information service website. JOURNAL OFMEDICAL INFORMATICS,2010,31(8):52-55

21.   Yuan zhongyu,Shusen Wang, et al.  Clinical Characteristics and Prognosis ofTriple-Negative Breast Cancer: A Report of 305 Cases. Chinese Journal ofCancer, 2008, 27(6)..

22.   Yuan zhongyu,Shusen Wang, et al. Clinical characteristics and prognosis ofdifferent subtypes of breast cancer Chinese Journal of Oncology.  2008 ,30(6):456-61

23.   Fu xiaohong, Wang shusen, Huang yan,el al. Prognostic significance of CD20expression in Hodgkin and Reed-sternberg cells of classical hodgkin’s lymphoma.Chinesr journal of cancer 2008,27(11):1197-1203

24.   CAO Ya –Bing, WANG Shu-Sen, HUANG Hui-Qiang et al.Primary Breast Lymphoma —A Report of 27 Cases withLiterature Review Chinese Journalof Cancer, 2007, 26( 1) : 84- 89

25.   Xiao Jian, Wang Shusen, Huang Yan et al.  Expression of CD117 and PDGFRa in ExtranodularNK/T Cell Lymphoma (Nasal Type) .Chinese Journal of Clinical Oncology2,007 34(11):615-617

26.   QIU Miao-Zhen, XUFei, WANG Shu-Sen et al.Responses of 109 Adult Soft Tis sue Sarcoma Patientsto Chemotherapy .Chinese Journal of Cancer, 2007, 26( 12) : 1344- 1349

27.    Shusen Wang, Zhongzhen Guan, et al. The Significance of EGFR and p-ERK Expressionin Nasopharyngeal Carcinoma，Chinese Journal of Oncology.2006,28(1).

28.    Shusen Wang, Zhongzhen Guan, et al. The Significance of c-Fos, and Cyclin-D1Expression in Nasopharyngeal Carcinoma，Chinese Journalof Clinical Oncology，2005,32,(6)

29.    Shusen Wang, Zhongzhen Guan, et al. In vivo Study of Epidermal Growth FactorReceptor-Selective Tyrosine Kinase Inhibitor Gefitinib on NasopharyngealCarcinoma. Chinese Journal of Cancer, 2004,23(11s).

30.   Yanqun Xiang, Shusen Wang, et al Prognostic Value ofSurviving and Living in Nasopharyngeal Carcinoma, The Laryngoscope, 116(1).

31.    Shusen Wang, Zhongzhen Guan, et al. Angiogenesis Modulator and Tumor. ChineseJournal of Medicine.2004, 4(1): 24-29.

32.    Shusen Wang, Tongyu Lin, et al. Anti-Cancer Therapy Targeting EGFR. ChineseJournal of Cancer Palliative Medicine. 2003,2(4): 239-242.

33.    Shusen Wang, Wenqi Jiang. Improving the Level of Clinical Study According toGood Clinical Practice. National Medical Journal of China.2003,83(3):179-180.

34.    Shusen Wang , Ruilin Wang, et al. Study on the Purification of AngiogenesisInhibitor from Shark Cartilage and its Biological Characteristics. HenanJournal of Oncololgy.1999, 12(3): 179-181.

35.    Shusen Wang, Lisong Tan, et al. A Study on the Method Using 1H11 EndothelialCells to Assay Angiogenesis Inhibitor. ACTA Academiae Medicinae Xuzhou. 1998,18 (3): 176-178.

36.   Jinchuan Zhang, Shusen Wang, et al. Detecting TumorSpecific Growth Factor in Patients with Chemotherapy. Academiae MedicinaeXuzhou.2001, 21(2): 116-117.

37.   Desheng liu, Shusen Wang et al. How to Improve theEffect and Safety of Three-Step Method of Analgesia. Chinese Journal ofClinical Oncology and Recovery.1999, 6 (5): 77-79. 

Updated by International Office, Sun Yat-sen University Cancer Center

Clinical and translational research for lymphoma, head and neck cancer (including nasopharyngeal cancer). Especially development of novel drugs, prognostic and predictive markers for these tumors, conduct of phase I and II clinical trials to test drugs.

Bachelor of Medicine, Sun Yat-Sen University of Medical Sciences, China, 1992-1997

Ph.D. in Oncology, Sun Yat-sen University, China, 1997-2002

Post Doctorate, Sun Yat-sen University Cancer Center, China, 2002-2004

Visiting scholar, Oncology Institute of Southern Switzerland, Switzerland, 2011-2012

Selected publications

1. Metronomic combination chemotherapy using everolimus and etoposide for the treatment of non-Hodgkin lymphoma. Wu K, Sun XQ, Wang CQ, Gao TX, Sun P, Wang Y, Jiang WQ, Li ZM#, Huang JJ#. Cancer Med 2020

2. High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China. Chen C, Sun P, Cui J, Yan SM, Chen H, Xia Y, Bi XW, Liu PP, Wang Y, Yang H, Nie M, Zhang XW, Jiang WQ, Li ZM#. Cancer Med 2019

3. Mutation Profiling of Malignant Lymphoma by Next-Generation Sequencing of Circulating Cell-Free DNA. Sun P*, Chen C*, Xia Y*, Wang Y, Liu PP, Bi XW, Shao YW, Ou QX, Wu X, Yang H, Nie M, Zhang XW, Li ZM#, Jiang WQ#. Journal of Cancer 2019

4. Trends in Survival of Patients With Primary Gastric Diffuse Large B-Cell Lymphoma: An Analysis of 7051 Cases in the SEER Database. Liu PP, Xia Y, Bi XW, Wang Y, Sun P, Yang H, Li ZM#, Jiang WQ#. Dis Markers 2018

5. A Comparison of R-EPOCH and R-CHOP as a First-Line Regimen in De Novo DLBCL Patients With High Ki-67 Expression in a Single Institution. Huang JJ, Xia Y, Wang Y, Liu PP, Bi XW, Sun P, Lin TY, Jiang WQ, Li ZM#. Oncotarget, 2016

6. Racial Patterns of Patients With Primary Mediastinal Large B-cell Lymphoma: SEER Analysis. Liu PP*, Wang KF*, Xia Y, Bi XW, Sun P, Wang Y, Li ZM#, Jiang WQ#. Medicine (Baltimore) 2016

7. High risk of deep vein thrombosis associated with peripherally inserted central catheters in lymphoma. Zhang X*, Huang JJ*, Xia Y*, Li CF, Wang Y, Liu PP, Bi XW, Sun P, Lin TY, Jiang WQ, Li ZM#. Oncotarget, 2016

8. Consolidative treatment after salvage chemotherapy improves prognosis in patients with relapsed extranodal natural killer/T-cell lymphoma. Nie M*, Bi XW*, Zhang WW*, Sun P, Xia Y, Liu PP, Huang HQ, Jiang WQ, Li ZM#. Sci Rep 2016

9. Effect of Rituximab on Adult Burkitt's Lymphoma: A Systematic Review and Meta-Analysis. Nie M*, Wang Y*, Bi XW, Xia Y, Sun P, Liu PP, Li ZM#, Jiang WQ#. Ann Hematol 2016

10. Prognostic values of interim and post-therapy 18F-FDG PET/CT scanning in adult patients with Burkitt’s lymphoma. Wei WX*, Huang JJ*, Li WY, Zhang X, Xia Y, Jiang WQ, Fan W#, Li ZM#. Chin J Cancer 2015

11. Expression of BAFF-R, but Not BAFF, Is an Independent Prognostic Factor in Diffuse Large B-cell Lymphoma Patients Treated With R-CHOP. Wang Y*, Li YJ*, Jiang WQ, Rao HL, Huang JJ, Xia Y, Bi XW, Sun P, Huang HQ, Lin TY, Guan ZZ, Li ZM#. Ann Hematol, 2015

12. Radiotherapy and PGEMOX/GELOX regimen improved prognosis in elderly patients with early-stage extranodal NK/T-cell lymphoma. Bi XW*, Xia Y*, Zhang WW, Sun P, Liu PP, Wang Y, Huang JJ, Jiang WQ, Li ZM#. Ann Hematol 2015

13. Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma in the Elderly: A Matched Case-Control Analysis. Song CG*, Huang JJ*, Li YJ*, Xia Y, Wang Y, Bi XW, Jiang WQ, Huang HQ, Lin TY, Li ZM#. PLoS One 2015

14. Treatment outcome of patients with advanced stage natural killer/T-cell lymphoma: elucidating the effects of asparaginase and postchemotherapeutic radiotherapy. Bi XW*, Jiang WQ*, Zhang WW, Huang JJ, Xia Y, Wang Y, Sun P, Li ZM#. Ann Hematol 2015

15. High APRIL but not BAFF serum levels are associated with poor outcome in patients with follicular lymphoma. Li YJ*, Li ZM*, Xia ZJ, Li S, Xia Y, Huang HQ, Huang JJ, Yi PY#, Jiang WQ#. Ann Hematol 2015

16. Prognostic Value of Interim and Posttherapy 18F-FDG PET/CT in Patients with Mature T-Cell and Natural Killer Cell Lymphomas. Ya-Jun Li*, Li ZM*, Xi-Ya Xia*, Huang HQ, Xia ZJ, Lin TY, Li S, Xia Y, Cai XY, Jiang WQ#. J Nucl Med 2013

17. Absolute Lymphocyte Count Is a Novel Prognostic Indicator in Extranodal Natural killer/T-cell Lymphoma, Nasal Type. Huang JJ*, Jiang WQ*, Lin TY, Huang Y, Xu RH, Huang HQ, Li ZM#. Ann Oncol 2011

18. Beclin 1 expression: A predictor of prognosis in patients with extranodal natural killer T-cell lymphoma, nasal type. Huang JJ, Li HR, Huang Y, Jiang WQ, Xu RH, Huang HQ, Lv Y, Xia ZJ, Zhu XF, Lin TY#, Li ZM#. Autophagy 2010

Updated May 2020 by International Office, Sun Yat-sen University Cancer Center

Selected Publications
1. Hua X*, Bi XW*, Zhao JL*, Shi YX*, Lin Y, Wu ZY, Zhang YQ, Zhang LH, Zhang AQ, Huang H, Liu XM, Xu F, Guo Y, Xia W, Hong RX, Jiang KK, Xue C, An X, Zhong YY, Wang SS*, Huang JJ*, Yuan ZY*. Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002).  Clin Cancer Res. 2022; 28(4):637-645.

2. Wang X*, Wang SS*, Huang H, Cai L, Zhao L, Peng RJ, Lin Y, Tang J, Zeng J, Zhang LH, Ke YL, Wang XM, Liu XM, Chen QJ, Zhang AQ, Xu F, Bi XW, Huang JJ, Li JB, Pang DM, Xue C, Shi YX, He ZY, Lin HX, An X, Xia W, Cao Y, Guo Y, Su YH, Hua X, Wang XY, Hong RX, Jiang KK, Song CG, Huang ZZ, Shi W, Zhong YY, Yuan ZY*; South China Breast Cancer Group (SCBCG). Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial. JAMA. 2021; 325(1):50-58. 

3. Su Y*, Huang J*, Wang S, Unger JM, Arias-Fuenzalida J, Shi Y, Li J, Gao Y, Shi W, Wang X, Peng R, Xu F, An X, Xue C, Xia W, Hong R, Zhong Y, Lin Y, Huang H, Zhang A, Zhang L, Cai L, Zhang J, Yuan Z*. The Effects of Ganglioside-Monosialic Acid in Taxane-Induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial. J Natl Cancer Inst. 2020;112(1):55-62.

4. Su Y*, Zhang Y*, Hua X, Huang J, Bi X, Xia W, Wang X, Huang Z, Song C, Zhong Y, Shi Y, Wang S; Fan W*, Yuan Z*. High-dose tamoxifen in high-hormone-receptor-expressing advanced breast cancer patients: a phase II pilot study. Adv Med Oncol. 2021; 13: 1–9.

5. Duan FF, Li JP, Huang JJ, Hua X, Song CG, Wang L, Bi XW, Xia W, Yuan ZY. Establishment and Validation of Prognostic Nomograms Based on Serum Copper Level for Patients With Early-Stage Triple-Negative Breast Cancer.  Front Cell Dev Biol. 2021;9:770115.

6. Hua X*, Huang X*, Huang ZZ*, Song CG, Deng JP, Long ZQ, Lin HX, Yuan ZY*. Establishment of prognostic nomograms based on skeletal muscle index and serum biomarker in breast cancer patients receiving radiotherapy. Clin Transl Med. 2020;10(2):e115.

7. Wang X*, Bi X*, Huang Z*, Huang J, Xia W, Shi W, Yuan Z*. The prognostic value of androgen receptor (AR) in HER2-enriched metastatic breast cancer. Endocr Relat Cancer. 2020; 27:199-208.

8. Wang X*, Li J*, Shi W, Huang Z, Xia W, Huang J, Su Y, Wang S, Shi Y, Bi X*, Yuan Z*. Efficacy of Moxifloxacin plus Treatment of Physician's Choice in Patients with Metastatic Breast Cancer. Oncologist. 2020; 25(10):e1439-45.

9. Xiong Z*, Ye L*, Zhenyu H*, Li F, Xiong Y, Lin C, Wu X, Deng G, Shi W, Song L, Yuan Z*, Wang X*. ANP32E induces tumorigenesis of triple-negative breast cancer cells by upregulating E2F1. Mol Oncol. 2018; 12(6):896-912.

10. Cui Y*, Ma W*, Lei F*, Li Q, Su Y, Lin X, Lin C, Zhang X, Ye L, Wu S, Li J, Yuan Z*, Song L*. Prostate tumour overexpressed-1 promotes tumourigenicity in human breast cancer via activation of Wnt/β-catenin signalling.  J Pathol. 2016;239:297–308.

Updated June 2022 by International Office, Sun Yat-sen University Cancer Center

2000/08-2004/08   
Department of respiration medicine, Affiliated hospital of Guilin Medical College, Resident   and  attending physician

2004/09-2007/06   
Department of MedicalOncology, Cancer center of Sun Yat-sen University,Master of oncology

2007/07-2010/07 
Department of Medical Oncology, Cancer center of Sun Yat-senUniversity, Oncology training Physician

2010/08-Present   
Department of Medical Oncology, Cancer center of Sun Yat-sen University, Attending Physician

Clinical and basic research inmedical oncology and translational medicine,especially in diagnosis and therapy for the gastrointestinal tumor.

1995/09-2000/07    Faculty of Clinical medicine in Guangxi Medical  University, Bachelor of medicine

2004/09-2007/06    Department of Medical Oncology, Cancer center of Sun Yat-sen University, Master ofoncology

2007/07-2010/07    Department of Medical Oncology, Cancer center of  Sun Yat-senUniversity, Oncology training Physician

2012.9-Present       PhD candidate

1.       Zeng ZL, Luo HY, Yang J, Wu WJ, Chen DL, Huang P, Xu RH. Overexpression of the circadian clock gene bmal1increases sensitivity to oxaliplatin in colorectal cancer. Clin Cancer Res. 2014 Feb 15;20(4):1042-52.

2.       Wang DS, Luo HY, Qiu MZ, Wang ZQ, Zhang DS, Wang FH, Li YH, Xu RH.Comparison of the prognostic values of various inflammation based factors inpatients with pancreatic cancer. Med Oncol. 2012Dec;29(5):3092-100.

3.        Luo HY, Wang ZQ, Wang FH, Qiu MZ, Teng KY, RuanDY, He YJ, Li YH, Xu RH. Phase 2 study of capecitabine and irinotecancombination chemotherapy (modified XELIRI regimen) in patients with advancedgastric cancer. Am J Clin Oncol. 2011 Dec;34(6):555-60.

4.       Qiu MZ, Wang ZQ, Luo HY, Zhang DS, Zhou ZW, Li YH, JiangWQ, Xu RH. Prognostic analysis in node-negative gastric cancer patients inChina.Tumour Biol. 2011 Jun;32(3):489-92.

5.       Li FH, Shen L, Li ZH, Luo HY, Qiu MZ, Zhang HZ, Li YH, XuRH.Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectalcancer. World J Gastroenterol. 2010 Dec 14;16(46):5881-8.

6.       Qiu MZ, Han B, Luo HY, Zhou ZW, Wang ZQ, Wang FH, LiYH, Xu RH. Expressions of hypoxia-inducible factor-1α and hexokinase-II ingastric adenocarcinoma: the impact on prognosis and correlation toclinicopathologic features.Tumour Biol. 2011 Feb;32(1):159-66.

7.        Luo HY, Wei W, Shi YX, Chen XQ, Li YH, Wang F, QiuMZ, Li FH, Yan SL, Zeng MS, Huang P, Xu RH.Cetuximab enhances the effect ofoxaliplatin on hypoxic gastric cancer cell lines.Oncol Rep. 2010Jun;23(6):1735-45.

8.        Luo HY, Xu RH, Wang F, Qiu MZ, Li YH, Li FH, ZhouZW, Chen XQ.Phase II trial of XELOX as first-line treatment for patients withadvanced gastric cancer. Chemotherapy. 2010;56(2):94-100.

9.       Li YH, Luo HY, Wang FH, Wang ZQ, Qiu MZ, Shi YX, Xiang XJ, Chen XQ, He YJ,Xu RH.Phase II study of capecitabine plus oxaliplatin (XELOX) as first-linetreatment and followed by maintenance of capecitabine in patients withmetastatic colorectal cancer.J Cancer Res Clin Oncol. 2010 Apr;136(4):503-10. 

Updated by International Office, Sun Yat-sen University Cancer Center

Dr. Ying Liang is an Associate professor of Department of Medical Oncology, Sun Yat-sen University Cancer Center. Dr. Liang obtained her MD and PhD degree at Sun Yat-sen University of Medical Sciences in 2000 and 2009, respectively. She has been working in Sun Yat-sen University Cancer Center since 2002. From 2013 to 2014, she studied at Stanford Cancer Institute, Stanford University School of Medicine. Dr. Liang’s major research interests are medical treatment and research on thoracic malignancies (non-small cell lung cancer, small cell lung cancer, thymic malignancy, malignant pleural mesothelioma, esophageal cancer, etc.), lymphoepithelioma-like carcinoma and nasopharyngeal carcinoma. Dr. Liang has authored or coauthored more than 40 peer-reviewed articles in scientific journals including Cancer, British Journal of Caner, Annals of Surgical Oncology, Lung Cancer and Clinical Lung Cancer, ect. She has participated in many international randomized control studies, SFDA approved clinical trials, investigator initiated trials and phase I trials. Dr. Liang is a member of International Association for the Study of Lung Cancer (IASLC), International Thymic Malignancies Interest Group (ITMIG) Dr. Liang serves on the editorial boards of Translational Lung Cancer Research, and the invited reviewer of Journal of Thoracic Oncology, Lung Cancer, Journal of Thoracic Disease, BMC Case Report.

Updated by International Office, Sun Yat-sen University Cancer Center

Updated by International Office, Sun Yat-sen University Cancer Center

Work experience

Jul 1996-Sep 2000  Yi Ji Shan Hospital, Wan nan Medical College

Jul 2003-Dec 2005  Sun Yat-sen University Cancer Center

Dec 2005-Dec 2010  Attending Physician. Sun Yat-sen University Cancer Center.

Dec 2010-present  Associate Professor Medical Oncolgy, Sun Yat-sen University Cancer Center.

1991-1996   Wan Nan Medical College, WuHu City, AnHuiProvince, P. R. China. Bachelor of Medicine (equivalent to US MD)

2000-2003   Yat-sen University, Guangzhou, P. R. China.Master of Medicine in Oncology

2005-2009   Yat-sen University, Guangzhou, P. R. China. Doctordegree of Medicine in Oncology

1. Zhang DS, Wang DS,Wang ZQ, Wang FH, Luo HY, Qiu MZ, Wang F, Li YH, Xu RH. Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabineadministered to Chinese patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2013Apr;71(4):1065-72. doi: 10.1007/s00280-013-2102-4. Epub 2013 Mar 13.

2. Li S, Zhang DS (co-first author), Sun J, Li Z, Deng L, Zou B, Zhan J, Jiang W Pharmacokinetics and tolerability of human mouse chimeric anti-CD22 monoclonalantibody in Chinese patients with CD22-positive non-Hodgkin lymphoma.MAbs. 2012 Mar 1;4(2). [Epub ahead of print]

3. Qiu MZ, Zhang DS (co-firstauthor), Ruan DY, Luo HY, Wang ZQ, Zhou ZW, Wang FH, Li YH, Xu RH. A relationship between ABO blood groups and clinicopathologiccharacteristics of patients with gastric adenocarcinoma in China.Med Oncol. 2011 Dec;28 Suppl 1:S268-73.doi: 10.1007/s12032-010-9735-5. Epub 2010 Nov 4.

4. Liu TZ, Zhang DS, LiangY, Zhou NN, Gao HF, Liu KJ, Wu HY Treatment strategiesand prognostic factors of patients with primary germ cell tumors in themediastinum. JCancer Res Clin Oncol. 2011 Nov;137(11):1607-12. doi:10.1007/s00432-011-1028-7. Epub 2011 Aug 18.

5. Wang DS, ZhangDS, Qiu MZ, Wang ZQ, Luo HY, Wang FH, Li YH, Xu RH. Prognostic factors and survival in patients with neuroendocrine tumors ofthe pancreas. Tumour Biol. 2011 Aug;32(4):697-705. doi: 10.1007/s13277-011-0170-9. Epub 2011Apr 9.

6. Qiu MZ, Wang ZQ, ZhangDS, Luo HY, Zhou ZW, Wang FH, Li YH, Jiang WQ, Xu RH. Clinicopathological characteristics and prognostic analysis of gastriccancer in the young adult in China. Tumour Biol. 2011 Jun;32(3):509-14. doi:10.1007/s13277-010-0145-2. Epub 2010 Dec 23.

7. Qiu MZ, Wang ZQ, ZhangDS, Liu Q, Luo HY, Zhou ZW, Li YH, Jiang WQ, Xu RH. Comparison of 6th and 7th AJCC TNM staging classification for carcinomaof the stomach in China. Ann Surg Oncol. 2011 Jul;18(7):1869-76. doi:10.1245/s10434-010-1542-x. Epub 2011 Jan 19.

8. Qiu MZ, Cai MY, ZhangDS, Wang ZQ, Wang DS, Li YH, Xu RH. Clinicopathologicalcharacteristics and prognostic analysis of Lauren classification in gastricadenocarcinoma in China.J Transl Med. 2013 Mar 6;11:58. doi: 10.1186/1479-5876-11-58.

9. Wang F, Xu RH, Luo HY, Zhang DS, Jiang WQ, Huang HQ, Sun XF, Xia ZJ, Guan ZZ. Clinical and prognostic analysis of hepatitis B virus infection indiffuse large B-cell lymphoma. BMC Cancer. 2008 Apr 23;8:115. doi:10.1186/1471-2407-8-115.

10. ZHANG Dong-sheng; JIANG Wen-qi;LI Su; et al. Expression of Glycoprotein 90K in Non-Hodgkin sLymphoma and Its Clinical  Significance .Chinese Journal of Cancer 2005;08.

11. ZHANGDong-sheng; JIANG Wen-qi; LI Su; et al. Detection of serun 90K/Mac-2BP in non-Hodgkin slymphoma and its clinical significance.Chian Oconlogy,2006；6.

Updated by International Office, Sun Yat-sen University Cancer Center

1995-2000:Medical College, Sun Yat-Sen University. Awarded a Bachelor degree of Medicine.      

2003-2007: Sun Yat-Sen University.Awarded a Master degree of Clinical Oncology.                          

2007-2011: Sun Yat-SenUniversity. Awarded a PhD degree of Oncology.                                  

2008-2010: Karolinska Institutet,Sweden. Collaborative training for PhD student.

1. de Miranda NF, Peng R, Georgiou K, Wu C,Falk Sörqvist E, Berglund M, Chen L, Gao Z, Lagerstedt K, Lisboa S, Roos F, vanWezel T, Teixeira MR, Rosenquist R, Sundström C, Enblad G, Nilsson M, Zeng Y,Kipling D, Pan-Hammarström Q. 2013. DNA repair genes are selectively mutated indiffuse large B cell lymphomas. J Exp Med 210: 1729-42. [co-first author].                                           

2. DuL, Peng RJ, Bjorkman A, Filipe de Miranda N, Rosner C, Kotnis A, Berglund M,Liu C, Rosenquist R, Enblad G, Sundstrom C, Hojjat-Farsangi M, Rabbani H,Teixeira MR, Revy P, Durandy A, Zeng Y, Gennery AR, de Villartay JP,Pan-Hammarstrom Q. 2012. Cernunnos influences human immunoglobulin class switchrecombination and may be associated with B cell lymphomagenesis. J Exp Med 209:291-305. [co-first author].                                

3. Peng RJ, Huang ZF, Zhang YL, Yuan ZY, XiaY, Jiang WQ, Zeng YX, Li J. 2011. Circulating and tumor-infiltrating Foxp3(+)regulatory T cell subset in Chinese patients with extranodal NK/T celllymphoma. Int J Biol Sci 7: 1027-36.                                                                   

4. Peng RJ, Wang S, Shi Y, LiuD, Teng X, Qin T, Zeng Y, Yuan Z. 2011. Patients 35 years old or younger withoperable breast cancer are more at risk for relapse and survival: aretrospective matched case-control study. Breast 20: 568-73.                                                                   

5. Xia Q, Cai Y, Peng RJ, Wu G, Shi Y, JiangW. 2014. The CDK1 inhibitor RO3306 improves the response of BRCA-proficientbreast cancer cells to PARP inhibition. Int J Onco 44:735-44.                                     

6. Tan DE, Foo JN, Bei JX, Chang J, Peng RJ, Zheng X, Wei L, HuangY, Lim WY, Li J, Cui Q, Chew SH, Ebstein RP, Kuperan P, Lim ST, Tao M, Tan SH,Wong A, Wong GC, Tan SY, Ng SB, Zeng YX, Khor CC, Lin D, Seow AL, Jia WH, LiuJ. 2013. Genome-wide association study of B cell non-Hodgkin lymphomaidentifies 3q27 as a susceptibility locus in the Chinese population. Nat Genet45:804-7.                                                                         

7. Qin T, Yuan Z, Peng RJ, Bai B, Shi Y, TengX, Liu D, Wang S. 2013. HER2-positive breast cancer patients receivingtrastuzumab treatment obtain prognosis comparable with that of HER2-negativebreast cancer patients. Onco Targets Ther 6:341-7.                                                                                             

8. Xue C, Wang X, Peng RJ, Shi Y, Qin T,Liu D, Teng X, Wang S, Zhang L, Yuan Z. 2012. Distribution, clinicopathologicfeatures and survival of breast cancer subtypes in Southern China. Cancer Sci103: 1679-83.                         

9. Shi YX, Xia Q, Peng RJ, Yuan ZY, Wang SS, An X, Cao Y, TanYT, Jin Y, Cai XY, Sun YL, Teng XY, Liu DG, Jiang WQ. 2012. Comparison ofclinicopathological characteristics and prognoses between bilateral andunilateral breast cancer. J Cancer Res Clin Oncol 138: 705-14.                                                                             

10.Shi YX, Tan YT, Yuan ZY, Wang SS, Peng RJ, AnX, Cao Y, Jin Y, Cai XY, Sun YL, Teng XY, Liu DG. 2012. Comparison of overallsurvival between the early use and delayed use of Trastuzumab therapy groups: aretrospective analysis of 128 patients with HER-2-positive advanced breastcancer. Med Oncol 29: 39-47.                                     

11. Wang X, Wang SS, Peng RJ, Qin T, Shi YX, Teng XY,Liu DG, Chen WQ, Yuan ZY. 2012. Interaction of coping styles and psychologicalstress on anxious and depressive symptoms in chinese breast cancer patients.Asian Pac J Cancer Prev 13: 1645-9.                                                                                              

12. Liu DG, Wang SS, Peng RJ, Qin T, Shi YX, TengXY, Wang X, Chen WQ, Yuan ZY. 2012. Interaction of social support andpsychological stress on anxiety and depressive symptoms in breast cancerpatients. Asian Pac J Cancer Prev 12: 2523-9.                                                                   

13. Liu D, He J, Yuan Z, Wang S, Peng RJ, Shi Y,Teng X, Qin T. 2012. EGFR expression correlates with decreased disease-freesurvival in triple-negative breast cancer: a retrospective analysis based on atissue microarray. Med Oncol 29: 401-5.                                                                                              

14. He J, Peng RJ, Yuan Z, Wang S, Peng J, Lin G,Jiang X, Qin T. 2012. Prognostic value of androgen receptor expression inoperable triple-negative breast cancer: a retrospective analysis based on atissue microarray. Med Oncol 29: 406-10.                                                             

15. Liu P, Fang X, Feng Z, Guo YM, Peng RJ, LiuT, Huang Z, Feng Y, Sun X, Xiong Z, Guo X, Pang SS, Wang B, Lv X, Feng FT, LiDJ, Chen LZ, Feng QS, Huang WL, Zeng MS, Bei JX, Zhang Y, Zeng YX. 2011. Directsequencing and characterization of a clinical isolate of Epstein-Barr virusfrom nasopharyngeal carcinoma tissue by using next-generation sequencingtechnology. J Virol 85: 11291-9.                                                                         

16. Gu AD, Mo HY, Xie YB, Peng RJ, Bei JX, Peng J,Li MY, Chen LZ, Feng QS, Jia WH, Zeng YX. 2008. Evaluation of a multianalyteprofiling assay and an enzyme-linked immunosorbent assay for serologicalexamination of Epstein-Barr virus-specific antibody responses in diagnosis ofnasopharyngeal carcinoma. Clin Vaccine Immunol 15: 1684-8.                                                                          

17. Peng RJ, Sun XF, Xiang XJ, Zhen ZJ, Ling JY,Tong GL, Xia Y, Xu GC, Jiang WQ. 2009. [Efficacy and survival of 92 cases ofEwing's sarcoma family of tumor initially treated with multidisciplinarytherapy]. Ai Zheng 28: 1304-9.                                                                                                 

18. Shi YX, Peng RJ, Lin SX, Wu QL, Lin TY, SunXF, Huang HQ, Xia ZJ, Li YH, Xu RH, Liu DG, Guan ZZ, Jiang WQ. 2007. [A survivalof 103 cases of T-cell non-Hodgkin lymphoma]. Zhonghua Nei Ke Za Zhi 46:1000-2.                                                                                

19. Shi YX, Han WJ, Peng RJ., etal. Screening of RNA Intervening Targets of foxp3 Gene with FLAG Fusion Peptideand Lentivirus Vector. Journal of Sun Yat-Sen University (Medical Sciences).2007,28(6):641-644.                        

20. Peng RJ, Q.M. Dong, Y.X. Shi, Y. Cao,Z.M. Zhou, Z.Y. Yuan, S. Li, H. Liao, W.Q. Jiang. 2006. Correlative analysisbetween serum dihydropyrimidine dehydrogenase, activity, concentration of5-fluorouracil and adverse events in the treatment of advanced gastric cancerpatients. Ai Zheng 25:1039-1043.                                                    

21. Liu, D.G., R.J. Peng, F.Y. Feng, X.H.Hu, G.D. Tang, J.P. Xiong, H.Y. Zhao, Y. Guo, and Z.Z. Guan. 2006. Randomizedcontrolled trial of two kinds of home-produced docetaxel in China for advancedbreast cancer. Ai Zheng 25:1557-1560.                                                                 

22. Li, Z.G., Y.X. Shi, R.J. Peng, M.Q. Zhu, andY.Y. Wan. 2006. Blocking enhancive effect of vascular endothelial growth factoron proliferation of rhabdomyosarcoma cell line RH4 by avastin. Ai Zheng25:718-722.                                                                             

23. Cao Y, Li HL, R.J. Peng, et al. Design stageI clinical trial of target, non-cytotoxic agents. Journal of Sun Yat-SenUniversity (Medical Sciences). 2006,28(4s): 44-46.

Updated by International Office, Sun Yat-sen University Cancer Center

1. Schedule-dependent synergistic effect of targeting mTOR/Beclin 1 mediated autophagy-dependent senescence in the combination with chemotherapy for patients of NHL. National Natural Science Funds for Distinguished Young Scholar. 2014-2016. Principal Investigator

2. Mechanism of targeting mTOR mediated autophagy-dependent senescence in lymphoma. Guangdong Natural Science Foundation. 2013-2015. Principal Investigator

1.Huang JJ, Li YJ, Xia Y, Wang Y, WeiWX, Zhu YJ, Lin TY, Huang HQ, Jiang WQ, Li ZM.Prognostic significance of peripheral monocyte count in patients withextranodal natural killer/T-cell lymphoma.BMC Cancer. 2013 May 3;13:222.

2.Huang JJ, ZhuYJ, Xia Y, Zhao W, Lin TY, Jiang WQ, Huang HQ, Li ZM.A novel prognostic model for extranodal natural killer/T-cell lymphoma.Med Oncol. 2012Sep;29(3):2183-90.

3.Li ZM,Huang JJ,Xia Y,Sun J,Huang Y,Wang Y,Zhu YJ,Li YJ,Zhao W,Wei WX,Lin TY,Huang HQ,Jiang WQ. Blood lymphocyte-to-monocyte ratio identifies high-riskpatients in diffuse large B-cell lymphoma treated with R-CHOP.PLoS One.2012;7(7):e41658.

4.Li ZM,Huang JJ,Xia Y,Zhu YJ,Zhao W,Wei WX,Jiang WQ,Lin TY,Huang HQ,Guan ZZ. High Ki-67 expression in diffuse large B-cell lymphomapatients with non-germinal center subtype indicates limited survival benefitfrom R-CHOP therapy.Eur J Haematol.2012 Jun;88(6):510-7.

5. Huang JJ, Li ZM, Huang Y, Huang Y,Tian Y, He XX, Xiao J, Lin TY.Schedule-dependent inhibition of T-cell lymphoma cells by cotreatmentwith the mTOR inhibitor everolimus and anticancer drugs.Invest New Drugs. 2012 Feb;30(1):223-35. 

6. Huang JJ, Zhu YJ, Lin TY, Jiang WQ,Huang HQ, Li ZM.Beclin 1 expression predicts favorable clinical outcome in patients withdiffuse large B-cell lymphoma treated with R-CHOP.Hum Pathol. 2011Oct;42(10):1459-66.

7.Zhu YJ,Huang JJ,Xia Y,Zhao W,Jiang WQ,Lin TY,Huang HQ,Li ZM. Primary mediastinal large B-cell lymphoma (PMLBCL) inChinese patients: clinical characteristics and prognostic factors.Int J Hematol.2011 Aug;94(2):178-84.

8. Huang JJ, Jiang WQ, Lin TY, Huang Y,Xu RH, Huang HQ, Li ZM.Absolute lymphocyte count is a novel prognostic indicator in extranodalnatural killer/T-cell lymphoma, nasal type.Ann Oncol. 2011 Jan;22(1):149-55.

9. Huang JJ, Li HR, Huang Y, Jiang WQ, XuRH, Huang HQ, Lv Y, Xia ZJ, Zhu XF, Lin TY, Li ZM.Beclin 1 expression: a predictor of prognosis in patients with extranodalnatural killer T-cell lymphoma, nasal type.Autophagy. 2010 Aug;6(6):777-83.

10. Huang JJ, Cai MY, Ye S, Li ZM, HuangHQ, Lin TY.Clinical analysis of 19 cases of subcutaneous panniculitis T-celllymphoma with literature review.Ai Zheng. 2009 Oct;28(10):1093-9.

11. Huang JJ, Lin TY.mTOR signal pathway and itsinhibitors in antitumor therapy: a review.Ai Zheng. 2007 Dec;26(12):1397-403. 

Updated by International Office, Sun Yat-sen University Cancer Center

1995/09~2000/07 Sun Yat-sen University of Medical Science, Bachelor of medicine 

2003/09~2009/06 Department of Medical Oncology, Cancer center of Sun Yat-sen University, Doctor of oncology

1. Serum C-reactive protein (CRP) as a simple and independent prognostic factor in extranodal natural killer/T-cell lymphoma, nasal type. PLoS One. 2013 May 28;8(5):e64158.Li YJ, Li ZM, Xia Y,et al.

2. Prognostic significance of peripheral monocyte count in patients with extranodal natural killer/T-cell lymphoma.BMC Cancer. 2013 May 3;13:222.Huang JJ, Li YJ, Xia Y, et al.

3. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.Eur J Haematol. 2012 Jun;88(6):510-517.Li ZM, Huang JJ, Xia Y,et al.

4. Clinical characteristics of the patients with Hodgkin's lymphoma involving extranodal sites.PLoS One. 2012;7(7):e41658.Li ZM, Huang JJ, Xia Y, et al.

5. Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP.Chin J Cancer. 2012 Jul;31(7):342-7.Li ZM, Zhu YJ, Xia Y,et al.

Updated by International Office, Sun Yat-sen University Cancer Center

Education:

9/2012-06/2015 PhD, Oncology, Sun Yat-sen University

(1)Qiu MZ#, Chen Q#, Zheng DY#, Zhao Q#, Wu QN#, Zhou ZW, Yang LQ, Luo QY, Sun YT, Lai MY, Yuan SS, Wang FH, Luo HY, Wang F, Li YH, Zhang HZ, Xu RH*. Precise microdissection of gastric mixed adeno-neuroendocrine carcinoma dissects its genomic landscape and evolutionary clonal origins. Cell Rep. 2023 Jun 6;42(6):112576. 
(2)Qiu MZ#, Zhang Y#, Guo Y, Guo W, Nian W, Liao W, Xu Z, Zhang W, Zhao HY, Wei X, Xue L, Tang W, Wu Y, Ren G, Wang L, Xi J, Jin Y, Li H, Hu C, Xu RH*. Evaluation of Safety of Treatment With Anti-Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial. JAMA Oncol. 2022 Jul 1;8(7):1042-1046. 
(3)Lin JF#, Hu PS#, Wang YY#, Tan YT#, Yu K, Liao K, Wu QN, Li T, Meng Q, Lin JZ, Liu ZX, Pu HY, Ju HQ*, Xu RH*, Qiu MZ*. Phosphorylated NFS1 weakens oxaliplatin-based chemosensitivity of colorectal cancer by preventing PANoptosis. Signal Transduct Target Ther. 2022 Feb 28;7(1):54. 
(4)Zhang Y#, Qiu MZ#, Wang JF, Zhang YQ, Shen A, Yuan XL, Zhang T, Wei XL, Zhao HY, Wang DS, Zhao Q, Xiong GZ, Ji YP, Liang XJ, Xia G, Xu RH*. Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma. Cell Rep Med. 2022 Nov 15;3(11):100814. 
(5)Zhang Z#, Wang ZX#, Chen YX#, Wu HX#, Yin L, Zhao Q, Luo HY, Zeng ZL, Qiu MZ*, Xu RH*. Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response. Genome Med. 2022 Apr 29;14(1):45. 
(6)Liu ZX#, Zhang XL#, Zhao Q#, Chen Y, Sheng H, He CY, Sun YT, Lai MY, Wu MQ, Zuo ZX, Wang W, Zhou ZW, Wang FH, Li YH, Xu RH*, Qiu MZ*. Whole-Exome Sequencing Among Chinese Patients With Hereditary Diffuse Gastric Cancer. JAMA Netw Open. 2022 Dec 1;5(12):e2245836. 
(7)Meng Q#, Lu YX#, Ruan DY#, Yu K, Chen YX, Xiao M, Wang Y, Liu ZX, Xu RH, Ju HQ*, Qiu MZ*. DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in gastric cancer. Mol Ther Nucleic Acids. 2021 Apr 3;24:695-710. 
(8)Luo F#, Lu FT#, Qiu MZ#, Zhou T, Ma WJ, Luo M, Zeng KM, Luo QY, Pan WT, Zhang L, Xia ZF, Zhang ZH, Cao JX, Zhao HY*, Zhang L*, Yang DJ*. Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway. Cell Death Dis. 2021 Aug 5;12(8):772.  
(9)He CY#, Qiu MZ#, Yang XH#, Zhou DL, Ma JJ, Long YK, Ye ZL, Xu BH, Zhao Q, Jin Y, Lu SX, Wang ZQ, Guan WL, Zhao BW, Zhou ZW, Shao JY*, Xu RH*. Classification of gastric cancer by EBV status combined with molecular profiling predicts patient prognosis. Clin Transl Med. 2020 Jan;10(1):353-362.
(10)Qiu MZ#, He CY#, Lu SX#, Guan WL, Wang F, Wang XJ, Jin Y, Wang FH, Li YH, Shao JY, Zhou ZW, Yun JP, Xu RH*. Prospective observation: Clinical utility of plasma Epstein-Barr virus DNA load in EBV-associated gastric carcinoma patients. Int J Cancer. 2020 Jan 1;146(1):272-280.  
(11)Luo QY#, Di T#, Chen ZG#, Peng JH, Sun J, Xia ZF, Pan WT, Luo F, Lu FT, Sun YT, Yang LQ, Zhang L*, Qiu MZ*, Yang DJ*. A novel prognostic model predicts overall survival in colon cancer based on RNA splicing regulation gene expression. Cancer Sci. 2022 Oct;113(10):3330-3346. 
(12)Luo QY#, Zhou SN#, Pan WT#, Sun J, Yang LQ, Zhang L*, Qiu MZ*, Yang DJ*. A multi-kinase inhibitor APG-2449 enhances the antitumor effect of ibrutinib in esophageal squamous cell carcinoma via EGFR/FAK pathway inhibition. Biochem Pharmacol. 2021 Jan;183:114318. 
(13)Sun YT#, Guan WL#, Zhao Q, Wang DS, Lu SX, He CY, Chen SZ, Wang FH, Li YH, Zhou ZW, Xu RH, Qiu MZ*. PD-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: a single-arm, open-label, phase 2 trial. Am J Cancer Res. 2021 Oct 15;11(10):5006-5015.   
(14)Qiu MZ#*, He CY#, Yang XH#, Yang LQ, Lin JZ, Zhou DL, Long YK, Guan WL, Jin Y, Li YH, Wang FH, Yang DJ*, Xu RH*. Relationship of HER2 Alteration and Microsatellite Instability Status in Colorectal Adenocarcinoma. Oncologist. 2021 Jul;26(7):e1161-e1170. 
(15)Li ZC#, Sun YT#, Lai MY#, Zhou YX*, Qiu MZ*. Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis. Int Immunopharmacol. 2022 Aug;109:108790. 

Updated by International Office, Sun Yat-sen University Cancer Center

Dr. Yaxiong Zhang is currently an attending doctor in the Department of Medical Oncology at Sun Yat-Sen University (SYSU) Cancer Center, Guangzhou, China. He mainly focuses on basic and clinical research of lung cancer. He has published more than 50 SCI-indexed papers in JNCI, Journal of Thoracic Oncology, Molecular cancer, Journal for ImmunoTherapy of Cancer, The Oncologist, Clinical Lung Cancer and other specialty periodical. Besides, he has won IASLC APLCC-Travel Grant Award and given poster presentation in ASCO, ESMO ESMO Asia and APLCC for many times.

1. Zhang Y, Chang L, Yang Y, Fang W, Guan Y, Wu A, Hong S, Zhou H, Chen G, Chen X et al: Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing. Molecular cancer 2019, 18(1):7.

2. Zhang Y, Chang L, Yang Y, Fang W, Guan Y, Wu A, Hong S, Zhou H, Chen G, Chen X et al: The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer. Journal for immunotherapy of cancer 2019, 7(1):98.

3. Zhang Y, Chang L, Fang W, Yang Y, Zhang L, Hong S, Zhou H, Guan Y, Yi X, Zhang L: Preferable background filtering for next-generation sequencing analysis in non-small cell lung cancer: pericarcinomatous tissues or peripheral blood lymphocytes? Cancer Communications (London, England) 2019, 39(1):33.

4. Zhang Z, Zhang Y, Chen G, Hong S, Yang Y, Fang W, Luo F, Chen X, Ma Y, Zhao Y et al: Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis. The oncologist 2018, 23(5):603-616.

5. Zhang Y, Zhou H, Zhang L: Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1? Journal for immunotherapy of cancer 2018, 6(1):135.

6. Zhang Y, Zhang Z, Huang X, Kang S, Chen G, Wu M, Miao S, Huang Y, Zhao H, Zhang L: Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials. Clinical lung cancer 2017, 18(5):e333-e340.

7. Zhang Y, Yang Y, Zhang Z, Fang W, Kang S, Luo Y, Sheng J, Zhan J, Hong S, Huang Y et al: Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis. Journal of the National Cancer Institute 2017, 109(2).

Updated by International Office, Sun Yat-sen University Cancer Center